The Office of Fair Trading has cleared the proposed acquisition by GlaxoSmithKline plc (GSK) of Maxinutrition Group Holdings Limited (Maxinutrition), a UK company that manufactures protein-enhanced functional nutrition products. GSK will acquire 100 per cent of the shares in Maxinutrition for a cash consideration of approximately £162m including the repayment of outstanding debt. The deal is intended to assist in extending GSK’s range of sports and health products and will complement its existing Nutritional Healthcare business which includes the sports and energy drinks brand, Lucozade.